The use of generic medications for hepatitis C

Liver International

Volumn 36, Issue 7, 2016, Pages 929-932

  Freeman, James A D ^a   Hill, Andrew ^b  

^a GP2U Telehealth   (Australia)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

direct acting antiviral; generic; hepatitis C; REDEMPTION 1

Indexed keywords

ANTIVIRUS AGENT; GENERIC DRUG; SOFOSBUVIR;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG COST; DRUG LEGISLATION; DRUG SAFETY; HEPATITIS C; HUMAN; LICENCE; MORALITY; PATENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC);

EID: 84979516880     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13157     Document Type: Article

References (16)

1. Hoen EF. The global politics of pharmaceutical monopoly power: drug patents, access, innovation and the application of the WTO Doha Declaration on TRIPS and public health. Diemen: AMB; 2009. 136 p. Available at http://apps.who.int/medicinedocs/documents/s20963en/s20963en.pdf. Accessed: 10 April 2016.
2. Boulet P, Garrison C, Hoen E. Drugs patents under the spotlight: Sharing practical knowledge about pharmaceutical patents. MSF. Geneva: SRO-Kundig; 2003 May. Available at http://www.who.int/3by5/en/patents_2003.pdf. Accessed: 10 April 2016
3. UNITAID. Hepatitis C medicine: Technology and market landscape – update. Switzerland: UNITAID; 2015. Available at http://www.unitaid.eu/images/marketdynamics/publications/Hepatitis_C_Medicines_Technology_and_Market_Landscape__Update.pdf. Accessed: 10 April 2016.
4. Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ 2012; 344: e4348.
5. Rubin R. Gilead avoids billions in U.S. Tax on its $1,000-a-Pill drug. [Place unknown]: Bloomberg; 2015 [updated 2015 Feb 27;]. Available at http://www.bloomberg.com/news/articles/2015-02-26/gilead-avoids-billions-in-u-s-taxes-on-its-1-000-a-pill-drug. Accessed: 10 April 2016.
6. Gilead. Data from Phase 3 Studies of Gilead's Sofosbuvir for Hepatitis C To Be Presented at 48th Annual EASL Meeting; Findings Published Online Today in The New England Journal of Medicine. Gilead; 2013. Available at http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1809511. Accessed: 10 April 2016.
7. Gilead. Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients. Gilead 2013 Available at http://www.gilead.com/news/press-releases/2013/12/gilead-announces-svr12-rates-from-three-phase-3-studies-evaluating-a-oncedaily-fixeddose-combination-of-sofosbuvir-and-ledipasvir-for-genotype-1-hepatitis-c-patients. Accessed: 10 April 2016.
8. Pharmacuetical Research and Manufacturers of America (PhRMA). Biopharmaceutical Industry-Sponsored Clinical Trials: Impact on State Economies. PhRMA; 2015 Available at http://www.phrma.org/sites/default/files/pdf/biopharmaceutical-industry-sponsored-clinical-trials-impact-on-state-economies.pdf. Accessed: 10 April 2016.
9. amfAR. Hepatitis C and drug pricing: The need for a better balance. Washington DC: amfAR; 2015. Available at http://www.amfar.org/uploadedFiles/_amfarorg/Articles/On_The_Hill/2015/amfAR%20HCV%20Issue%20Brief%20Feb%202015.pdf. Accessed: 10 April 2016.
10. World Health Organization. Hepatitis C. WHO; 2015 [updated 2015 July;]. Available at http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed: 10 April 2016.
11. Ishmael H. Gilead sciences Inc, AbbVieInc finally see growth in HCV prescription volumes. [Place unknown]: BIDNESS ETC; 2015. Available at http://www.bidnessetc.com/59228-gilead-sciences-inc-abbvie-inc-finally-see-growth-in-hcv-prescription-volum/. Accessed: 10 April 2016.
12. Pollack A. Harvoni, a Hepatitis C Drug From Gilead, Wins F.D.A. Approval. New York Times; 2014. Available at http://www.nytimes.com/2014/10/11/business/harvoni-a-hepatitis-c-drug-from-gilead-wins-fda-approval.html. Accessed: 10 April 2016.
13. Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Minimum costs for producing Hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis 2014; 58: 928–36.
14. World Health Organization. WHO Model Lists of Essential Medicines. WHO. Available at http://www.who.int/medicines/publications/essentialmedicines/en/. Accessed: 10 April 2016.
15. Reichman JH. Comment: Compulsory licensing of patented pharmaceutical inventions: evaluating the options. J Law Med Ethics 2009; 37: 247–63.
16. Freeman J. Reviewing DAA Efficacy Managing Patient Treatment In Online Neighborhoods (REDEMPTION). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2016. Available at https://clinicaltrials.gov/ct2/show/NCT02657694. Accessed: 10 April 2016.